TABLE 7.
Efficacy of Debio-025 in combination with 19 FDA-approved anti-HIV-1 drugs in CEM-SS cellsa
| Compound group and compound | Synergy vol (nM2 % or nM μM %) | Antagonism vol (nM2 % or nM μM %) |
|---|---|---|
| Nucleoside RT inhibitors | ||
| 3TC | 56.9 ± 27.9 | 7.0 ± 6.6 |
| ABC | 23.6 ± 17.5 | 22.3 ± 19.6 |
| AZT | 35.6 ± 39.4 | 43.4 ± 79.1 |
| d4T | 18.8 ± 28.5 | 10.1 ± 17.2 |
| ddC | 12.2 ± 10.9 | 15.8 ± 13.7 |
| ddI | 26.8 ± 37.3 | 20.3 ± 21.9 |
| FTC | 20.0 ± 25.5 | 9.7 ± 8.5 |
| TFV | 28.1 ± 26.0 | 12.7 ± 11.1 |
| Nonnucleoside RT inhibitors | ||
| DLV | 43.6 ± 37.4 | 16.4 ± 12.7 |
| EFV | 32.5 ± 34.1 | 17.7 ± 11.4 |
| NVP | 95.9 ± 63.3 | 18.0 ± 17.9 |
| Protease inhibitors | ||
| APV | 38.8 ± 34.4 | 0.1 ± 0.2 |
| ATV | 14.8 ± 22.9 | 44.1 ± 39.7 |
| IDV | 47.8 ± 29.7 | 24.9 ± 29.0 |
| LPV | 1.3 ± 1.5 | 30.1 ± 47.7 |
| NFV | 17.5 ± 17.3 | 38.3 ± 48.4 |
| RTV | 4.6 ± 7.7 | 20.4 ± 14.4 |
| SQV | 29.3 ± 34.9 | 26.7 ± 21.4 |
| Fusion inhibitor enfuvirtide | 27.8 ± 21.5 | 0 ± 0 |
a
HIV-1 strain IIIB-induced CPE; synergy and antagonism volumes were calculated at the 95% confidence level; values are means ± standard deviations from three to six independent determinations.